Web-based Alcohol-specific Inhibition Training in Adolescents and Young Adults With Alcohol Use Disorder
Launched by UNIVERSITY OF BERN · Jul 8, 2025
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is testing a new smartphone app designed to help young people with alcohol use disorder (AUD) improve their ability to resist alcohol in everyday situations. The app offers special training aimed at strengthening self-control specifically related to alcohol use. Researchers want to see if using this app alongside regular treatment is practical and if it can help reduce drinking and change how the brain responds to alcohol.
Young people between 14 and 27 years old who are already receiving treatment for AUD and meet certain drinking-related criteria might be eligible to join. Participants will be asked to use the app for six short training sessions, followed by six more sessions about a month later as a "booster." The study will compare those using the alcohol-specific training app with others doing a similar but non-alcohol-focused training. This research hopes to create an easy-to-use tool that supports young people in their recovery from alcohol problems.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 14 - 27 years
- • Alcohol use disorder identification test (AUDIT) ≥ 8
- • Alcohol use disorder scale (AUD-S) ≥ 2
- • Currently undergoing outpatient treatment or online counselling in one of 5 specialized treatment settings
- • Sufficient German language skills
- • Informed Consent as documented by signature
- • Owner of a smartphone with internet access
- Exclusion Criteria:
- • Other severe substance use (except nicotine and cannabis) determined by the cut-off value ≥ 25 in the drug use disorder identification test (DUDIT)
- • Current medical conditions excluding participation
- • Inability to read and understand the participant's information
- • Enrolment of the investigator, his/her family members, employees, and other dependent persons
- Additional exclusion criteria for Electroencephalography (EEG)-substudy:
- • Current medication affecting EEG (e.g., benzodiazepines)
- • Other severe substance use determined by the cut-off value ≥ 25 in the DUDIT (except nicotine)
- • History of epilepsy
About University Of Bern
The University of Bern, a leading research institution in Switzerland, is dedicated to advancing medical knowledge and improving patient care through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration and cutting-edge research, the university fosters an environment where scientific inquiry and clinical application intersect. Its commitment to ethical standards and patient safety ensures that all trials are conducted with the highest integrity, striving to contribute valuable insights to the global medical community. The University of Bern actively engages in diverse therapeutic areas, aiming to translate research findings into tangible health solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bern, , Switzerland
Patients applied
Trial Officials
Maria Stein, PD Dr.
Principal Investigator
University of Bern
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported